Molecular imaging of prostate cancer

Current Opinion in Urology

Volumn 22, Issue 4, 2012, Pages 320-327

  Fox, Josef J ^a   Schöder, Heiko ^a   Larson, Steven M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

16 fluoro 5a dihydrotestosterone; choline; fluorodeoxyglucose; positron emission tomography; prostate cancer

Indexed keywords

16BETA FLUORO 5ALPHA DIHYDROTESTOSTERONE F 18; ACETIC ACID C 11; CHOLINE C 11; CHOLINE F 18; FLUCICLOVINE F 18; FLUORODEOXYGLUCOSE F 18; METHIONINE C 11; PROSTATE SPECIFIC ANTIGEN; SODIUM FLUORIDE F 18; UNCLASSIFIED DRUG;

BONE METASTASIS; CANCER DIAGNOSIS; DRUG HALF LIFE; DRUG URINE LEVEL; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

AGED; BONE NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; WHOLE BODY IMAGING;

EID: 84862509374     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32835483d5     Document Type: Review

References (43)

1. Scher HI, Heller G. Clinical states in prostate cancer: towards a dynamic model of disease progression. Urology 2000; 55:323-327.
2. Scher HI, Morris MJ, Kelly WK, et al. Prostate cancer clinical trial end points: 'RECIST'ing a step backwards. Clin Cancer Res 2005; 11:5223-5232.
3. Bauman G, Belhocine T, Kovacs M, et al. 18F-fluorocholine for prostate cancer imaging: A systematic review of the literature. Prostate Cancer Prostatic Dis 2012; 15:45-55.
4. Souvatzoglou M, Weirich G, Schwarzenboeck S, et al. The sensitivity of[11C]choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res 2011; 17:3751-3759.
5. Scher HI, Eisenberger M, D'Amico AV, et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 2004; 22:537-556.
6. Krause BJ, Souvatzoglou M, Tuncel M, et al. The detection rate of [11C]choline- PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35:18-23.
7. Giovacchini G, Picchio M, Scattoni V, et al. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010; 37:1106-1116.
8. Giovacchini G, Picchio M, Parra RG, et al. Prostate-Specific Antigen Velocity Versus Prostate-Specific Antigen Doubling Time for Prediction of 11C Choline PET/CT in Prostate Cancer Patients With Biochemical Failure After Radical Prostatectomy. Clin Nucl Med 2012; 37:325-331.
9. Castellucci P, Fuccio C, Nanni C, et al. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med 2009; 50:1394-1400.
10. Schillaci O, Calabria F, Tavolozza M, et al. Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced (18)F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy. Eur J Nucl Med Mol Imaging 2012; 39:589-596.
11. Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum Path 2000; 31:578-583.
12. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
13. Subramanian G, McAfee JG. A new complex of 99mTc for skeletal imaging. Radiology 1971; 99:192-196.
14. Pollen JJ, Witztum KF, Ashburn WL. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. Am J Roentgenol 1984; 142: 773-776.
15. Grant FD, Fahey FH, Packard AB, et al. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med 2008; 49:68-78.
16. Blau M, Nagler W, Bender MA. Fluorine-18: A new isotope for bone scanning. J Nucl Med 1962; 3:332-334.
17. Segall G, Delbeke D, Stabin MG, et al. SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0. J Nucl Med 2010; 51:1813-1820.
18. Even-Sapir E, Metser U, Mishani E, et al. The detection of bone metastases in patients with high risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single and multi field of view SPECT, 18F-fluoride PET and 18F-fluoride PET/CT. J Nuc Med 2006; 47:287-297.
19. Imbriaco M, Larson SM, Yeung HW, et al. A new parameter for measuring metastatic bone involvement by prostate cancer: the bone scan index. Clin Cancer Res 1998; 4:1765-1772.
20. Sabbatini P, Larson SM, Kremer A, et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 1999; 17:948-957.
21. Meirelles GS, Schoder H, Ravizzini GC, et al. Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer. Clin Cancer Res 2010; 16:6093-6099.
22. Ulmert D, Kaboteh R, Fox JJ, et al. A Novel Automated Platform for Quantifying the Extent of Skeletal Tumour Involvement in Prostate Cancer Patients Using the Bone Scan Index. Eur Urol 2012. [Epub ahead of print]
23. Dennis ER, Jia X, Mezheritskiy IS, et al. Bone scan index: A quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol 2012; 30:519-524.
24. Sadik M, Suurkula M, Hö glund P, et al. Improved classifications of planar whole-body bone scans using a computer-assisted diagnosis system: A multicenter, multiple-reader, multiple-case study. J Nucl Med 2009; 50: 368-375.
25. Hillner BE, Siegel BA, Shields AF, et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med 2008; 49:1928-1935.
26. Hillner BE, Siegel BA, Liu D, et al. Impact of positron emission tomography/ computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol 2008; 26:2155-2161
27. Jadvar H. FDG PET in Prostate Cancer. PET Clin 2009; 4:155-161.
28. Schö der H, Herrmann K, Gö nen M, et al. 2-[18F]fluoro-2- deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 2005; 11:4761-4769.
29. Morris MJ, Akhurst T, Osman I, et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 2002; 59:913-918.
30. Morris MJ, Akhurst T, Larson SM, et al. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res 2005; 11: 3210-3216.
31. Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: A novel antiandrogen for prostate cancer treatment. Cancer Res 2012; 72:1494-1503.
32. Liu A, Dence CS, Welch MJ, Katzenellenbogen JA. Fluorine-18-labeled androgens: radiochemical synthesis and tissue distribution studies on six fluorine-substituted androgens, potential imaging agents for prostatic cancer. J Nucl Med 1992; 33:724-734.
33. Larson SM, Morris M, Gunther I, et al. Tumor localization of 16beta-18F-fluoro- 5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 2004; 45:366-373.
34. Dehdashti F, Picus J, Michalski JM, et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging 2005; 32:344-350.
35. Fox JJ, Autran-Blanc E, Morris MJ, et al. Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT. J Nucl Med 2011; 52:1727-1732.
36. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study. Lancet 2010; 375:1437-1446.
37. Pandit-Taskar N, O'Donoghue JA, Morris MJ, et al. Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability nd dosimetric projections for 90Y radioimmunotherapy. J Nucl Med 2008; 49:1066-074.
38. Wright GL Jr, Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996; 48:326-334.
39. Kuroda K, Liu H, Kim S, et al. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. Prostate 2009; 69:1579-1585.
40. Holland JP, Divilov V, Bander NH, et al. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med 2010; 51:1293-1300.
41. EVans MJ, Smith-Jones PM, Wongvipat J, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A 2011; 108:9578-9582.
42. Mease RC, Dusich CL, Foss CA, et al. N-[N-[(S)-1,3-Dicarboxypropyl] carbamoyl]- 4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: A new imaging probe for prostate cancer. Clin Cancer Res 2008; 14:3036-3043.
43. Scher HI, Morris MJ, Basch E, Heller G. End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol 2011; 29:3695-3704.